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A key aspect of reducing new knowledge to practice in the field of medicine is 
successfully navigating the process of patenting inventions and licensing them to 
facilitate their use. University faculty and their departments have much to gain 
from a detailed understanding of how this is done because even small deviations 
in laboratory practice, documentation, or execution of the process may com-
pletely negate possible benefits. Here we describe good laboratory practice for 
documentation of medical research, the process of patenting intellectual prop-
erty, and its potential impact on faculty and their departments. As the field of 
medicine rapidly changes, faculty and their departments who are knowledgeable 
about these issues will be best positioned to see their ideas converted into treat-
ments for disease.
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The purpose of medical research is 
to increase our understanding of the 
observable world so that discovery can 
be put into practice to reduce human 
suffering. Our understanding of skin 
biology and related medical science has 
advanced greatly since the Society for 
Investigative Dermatology was founded 
in 1937, and it promises to continue 
growing rapidly. An aspect of this enter-
prise that receives less attention than 
the discovery process is the reduction 
to practice of new knowledge. Once 
new insights and approaches to manage 
disease are uncovered, this knowledge 
must be integrated into the practice of 
medicine. Successfully moving discov-
ery into practice provides the deep sat-
isfaction of knowing that one’s research 
efforts have been worthwhile. Since the 
passage of the Bayh–Dole Act of 1980, 
which permitted universities to obtain 
patents and license inventions derived 
from government-funded research 
(Sampat, 2010), moving discovery into 
practice has also provided significant 
monetary benefits to investigators and 
their universities. If discoveries are 
transformative, the amounts of revenue 
generated can be very large. Because 
of this change in the law, patent grants 
to universities have increased from less 
than 300 a year in 1980 to more than 
3,000, with US universities collectively 
earning almost $2 billion each year 
(Sampat, 2010). For departments lucky 
enough to have faculty that make such 
discoveries, these monies can create 
endowments that allow a department 
to be more supportive of cutting-edge 
science, take advantage of opportuni-
ties, or provide resources to support 
outstanding faculty. An excellent exam-
ple of this is provided by the University 
of Pennsylvania—Albert Kligman did 
his seminal research on retinoic acid 
effects in skin while serving as a fac-
ulty member there, providing millions 
of dollars in royalties to the department 
to support its educational, research, and 
patient-care missions (Stanley, 2006).
Licensing of patent rights has also 
stimulated an increase in new univer-
sity-associated small businesses; as 
many as three are created per univer-
sity each year. More than two-thirds of 
these small companies were supported 
by universities taking equity positions in 
the company (AUTM Licensing Survey, 
http://www.autm.net/Surveys.htm). 
Royalty revenue can be big business 
for universities (although only about 
10% actually realize large returns), so 
ensuring that their technology-transfer 
office is effective in supporting fac-
ulty inventors is important (Bulut and 
Moschini, 2009). Proper stewardship of 
faculty patents and licensing can pro-
vide a significant percentage of univer-
sity revenue. In addition, the efficacy 
of university administrators, such as 
department chairs and the technology-
transfer office, varies greatly from one 
institution to another. Table 1 lists the 
total research funding and license rev-
enue for fiscal year 2009 at several uni-
versities, illustrating the diverse level of 
revenue that licensing provides to these 
institutions (AUTM Licensing Survey, 
http://www.autm.net/Surveys.htm).
For university researchers to realize 
the benefits of invention, the first step in 
the process is keeping an accurate and 
thorough record of the research being 
done. In its most stringent form, this 
process is called good laboratory prac-
tice (GLP). GLP is an approach to exper-
imentation and documentation that 
entails systematic controls on research 
quality as well as managing the research 
process to ensure uniformity, consisten-
cy, reliability, and reproducibility of the 
data. The process is required for data 
that are to be presented to the US Food 
and Drug Administration for assess-
ment of new drugs (Knight and Cree, 
2011). In a pharmaceutical manufac-
turing environment, rigorous attention 
is paid to standards and maintenance 
of the laboratory equipment, test facil-
ity operation, and documentation of 
personnel training. The origin of materi-
als; their quality, labeling, and storage; 
conduct of experiments to include all 
proper controls; and logs documenting 
these items are required. Key aspects of 
proper GLP documentation are summa-
rized in Table 2.
In the cutting-edge research 
conducted at universities, not all aspects 
of GLP are required, but thorough 
documentation of laboratory work is 
requisite. Determination of inventorship 
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can depend on defining the path of idea 
creation, so relevant discussions with 
others should also be documented, 
and corroborated in writing by those 
involved. It is especially important to 
document dates when discussions or 
experiments took place. The overall 
emphasis for documentation is that the 
researcher demonstrate diligence in 
the pursuit of discovery. Although data 
generated in the course of conduct-
ing scientific research do not neces-
sarily become the subject of a patent’s 
claims, data that are not directly part of 
the claims can be very important for the 
purpose of enabling the invention, and 
the documentation should be complete. 
Ultimately, the notebook is used to 
establish patentability, the date of inven-
tion, and inventorship. In academia, it 
should be made clear to all participants 
in the scientific process what their role 
is in the discovery. Students rotating 
through laboratories, graduate students, 
and postdoctoral fellows should clear-
ly understand whether their research 
activities constitute participation in the 
inventive process. Providing technical 
assistance for research does not consti-
tute a role in the inventive process. It is 
the responsibility of the principal inves-
tigator to ensure that everyone involved 
in the project understands this relation-
ship. Additionally, because disclosure 
of inventions to the public prior to pat-
ent filing can invalidate protection in 
some markets, students contributing 
to patentable research may face a con-
flict between being able to present their 
work and allowing the work to be pat-
ented. Principal investigators must be 
clear with students about such issues at 
all times.
Once a discovery is made, the next 
step in the process is securing patent 
protection (Pressman, 2011). This step 
can be problematic because public 
disclosure can lead to loss of patent 
rights. The investigator must recog-
nize the need for patent protection and 
file the patent application before any 
“enabling” disclosures are made to the 
general public. How does the patent-
ing process work? At a university, the 
invention must first be disclosed to the 
appropriate institutional department, 
usually the technology transfer office. 
Once a decision is made to seek patent 
protection, an application is drafted by 
a patent attorney. A patent application 
consists of several required sections: 
a description of the field covered by 
the patent, a description of related art 
that the new patent seeks to improve 
on, and a description of how the new 
invention is an improvement over back-
ground art or overcomes problems with 
existing art. If there are drawings, the 
drawings are described in detail.
The application next provides a 
detailed description of the invention. 
For example, if a gene was discovered, 
the sequence is listed in the detailed 
description. If it is a new computed 
tomography imaging device, it will 
show how the X-ray source is applied 
to the patient and how the signals are 
collected and present the mathematics 
of reconstructing the image for interpre-
tation. The preferred embodiment of the 
invention is then discussed. Inventions 
may be carried out in a variety of ways, 
but the inventor must describe the best 
way to make and/or use the invention, 
although other embodiments may also 
be described. The patent must describe 
the invention completely and in suf-
ficient detail that the reader with ordi-
nary skill in the field can understand 
how to make and/or use it. The heart of 
the patent application is a claim or list 
of claims that define the scope of pro-
tection that will be legally conferred if 
the patent is granted.
As an example, a very abbreviated 
set of claims from US Patent 7,888,392 
is presented in Table 3 (http://patft.
uspto.gov). A classic dermatologic 
invention, this patent describes an 
ointment containing a pharmaceuti-
cal agent that has an antipruritic effect 
in a vehicle with low skin irritancy and 
excellent storage stability. As this patent 
illustrates, claims are broken down into 
independent and dependent claims. Of 
the four listed, claims 1 and 2 are inde-
pendent and claims 3 and 4 are depen-
dent. Claim 1 teaches the formula for 
the ointment (together with reference 
to the diagram; not shown here), and 
claim 2 teaches the method of making 
the ointment. Claims 3 and 4 further 
describe aspects of claim 1; hence, they 
are dependent claims.
After the claims, the final portion of 
a patent application is a short (fewer 
than 150 words) abstract describing the 
invention. When the patent is issued, 
the abstract is placed on the front page, 
together with the patent number, date, 
and title. The inventors are then listed, 
and in cases in which the inventors 
have the duty to assign their rights to 
the invention to their institution, there 
is a listing for the assignee. There is also 
a list of patents and other publications 
that the Patent Office used as “prior art” 
during examination of the patent appli-
cation. Prior art becomes important in 
patent litigation if validity of the patent 
comes into question.
US patent law was written into the US 
Constitution in paragraph 8, section 8, 
of Article 1 and went into effect upon its 
signing. George Washington signed the 
first patent issued in the United States, 
table 1. royalty revenue at several major universities
Institution
total research 
funding ($)
royalty  
revenue ($)
royalty revenue as a 
percentage of the total
California Institute  
of Technology
521,436,800 47,665,535 9.1
Case Western  
Reserve
332,661,000 16,281,957 4.9
Columbia 604,660,000 154,257,579 25
Ohio State University 716,461,278 1,711,719 2.4
University of  
North Carolina
666,871,589 3,063,947 4.5
University  
of Rochester
337,246,000 46,025,270 13.6
Stanford 733,266,108 65,054,187 8.9
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on 31 July 1790. It was a dermatological 
patent for an ingredient used in mak-
ing soap, granted to Samuel Hopkins 
(Evans, 1919). The purpose of patenting 
an invention is to create incentive for a 
commercial entity to use its resources 
to develop that technology. The patent 
grants a limited monopoly to the patent 
holder for a finite time, potentially creat-
ing a strong business advantage. Without 
the benefit of this limited monopoly, 
businesses would not expend the time 
and expense to bring many products to 
market. After patent protection expires, 
the technology moves into the public 
domain and is available to all. Thus, 
a patent creates a favorable business 
advantage initially and subsequently 
stimulates science through disclosure of 
knowledge in the context of its advanta-
geous use (Evans, 1919).
For a discovery to be patentable, 
it must be novel, have utility, and be 
nonobvious (Pressman, 2011). Novelty 
is something that the inventor demon-
strates by showing that the invention is 
different from all prior art in the pub-
lic domain. Generally, the utility of an 
invention is quite clear—for example, 
the wheel on an automobile holds up 
the car. The nonobviousness require-
ment is the most difficult to meet. Patent 
examiners peruse previous patents and 
other publications in the public domain 
and can reject an application by find-
ing that the invention is a combination 
of existing concepts A, B, and C (i.e., 
something that anyone of ordinary skill 
could have created, even if no one else 
actually has). Such an application is 
therefore obvious based on the exist-
ing prior art, in combination. It is only 
when the inventor can successfully 
demonstrate novelty, utility, and nonob-
viousness that a patent will be granted.
Another important aspect of a pat-
ent’s validity is the correct designation 
of inventorship (Slowinski and Zerby, 
2008). Determination of inventorship 
relies heavily on correct documentation 
of the research supporting the patent 
application. The lineage of ideas and 
their ownership must be regularly docu-
mented during the research process for 
inventorship to be clear and uncon-
tested. Unlike scientific publications, 
patent inventorship is legally defined. 
With publications, it is possible to have 
someone who edited a manuscript 
but did not directly contribute to it be 
listed as an author. This is not the case 
with patents. Moreover, if a patent does 
not list the correct inventorship (e.g., 
if it lists “inventors” who do not meet 
the legal definition), it can be invali-
dated. Conversely, if it does not list all 
the inventors who contributed to the 
invention, it can also be found invalid. 
This becomes especially important dur-
ing patent litigation. Additionally, in 
the eyes of patent law, all inventors are 
equal, even if they actually contributed 
to only one dependent claim. Every 
inventor has the right to practice that 
invention and the right to keep others 
from practicing it.
Of course, effective practice of 
an invention means that some new 
medicine or machine must be pro-
duced and distributed by a competent 
commercial partner. The term used for 
permission to practice someone else’s 
invention is called a license (or licens-
ing agreement). Once it is clear that 
an invention can be developed into a 
useful device, therapy, or service, and 
it is determined that it would be com-
mercially feasible to use resources for 
its development, companies may enter 
into licensing agreements with univer-
sities to acquire permission to prac-
tice the invention. Such agreements 
provide the opportunity to create a 
revenue stream for the inventor, their 
department, and the university. To assist 
faculty in implementing their patented 
discoveries, institutions set up offices 
that manage their intellectual prop-
erty or hire outside entities (usually law 
firms) to manage their patent portfolios.
With the signing of the Leahy–Smith 
America Invents Act (H.R. 1249) on 16 
September 2011, the US patent system 
was transformed from a “first-to-invent” 
system to a standard common in the rest 
of the world, where patent rights are 
granted to the first inventors to file their 
application.
Formerly, an inventor had a one-year 
grace period after public disclosure 
of an invention to file a patent appli-
cation protecting it (Jackson, 1967). 
“Public disclosure” under the former 
law included printed publication, pre-
sentations, offers for sale, and certain 
public uses. The Leahy–Smith Act lim-
its the activities allowed by the inven-
tor under the one-year grace period to 
printed publications and public presen-
tations. Fortunately, research applica-
tions to the National Institutes of Health 
are not considered public disclosures. 
Retaining the grace period for publi-
cations by inventors is an important 
consideration for academic research-
ers. In academics, we must publish our 
work to advance our careers as well as 
to advance science. The publication 
grace period under the new patent law, 
although more limited than before, still 
provides a marked distinction between 
US patent law and most other first-to-
file systems. In many other countries, 
for patent rights to be preserved there 
must be absolute novelty. This means 
nothing can be in print, or otherwise 
available to the public, that enables 
one to practice the invention. Lack of 
table 2. Key features of laboratory notebooks in good laboratory practice
Bound notebook—do not remove any pages.
Entries are in ink.
No erasure marks—strike through the item and initial to indicate unwanted entries.
Experiments to be dated, with title, statement of objective, and a detailed description of the 
experiment being conducted.
Evaluation, interpretation, and conclusions about experiments are included.
All figures are labeled and abbreviations are defined. If data are to be attached to the notebook, 
they are taped in, with date, time, and signature.
Experiments are included in chronological order, and failed experiments are also included.
Timely signature and date by a witness who is not a coinventor.
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attention to this requirement can have 
huge consequences—public disclosure 
through public presentation or publica-
tion can cause an inventor to lose the 
opportunity to protect his or her inven-
tion in many big markets. In the case 
of topical dermatologic products, even 
limited production or sales of the inven-
tion cannot occur if patent rights are to 
be secured.
How does a university office of tech-
nology transfer support faculty in the 
process of obtaining patents for their 
inventions and facilitating their licens-
ing? Typically, once the office receives 
a disclosure, the commercial poten-
tial and the patentability are assessed 
(Miller et al., 2009). A prior art search 
is conducted because the inventor 
may be unaware that the invention has 
already been patented or otherwise 
disclosed. If there appears to be com-
mercial viability and true novelty, the 
office will file a patent application to 
protect the invention. This process will 
also demand some time from the facul-
ty member and must be done correctly 
for patent protection to be provided. 
It can be frustrating and complicated, 
but if successful, it is the key to trans-
lating research into practical, benefi-
cial change in science and medicine. 
Department administrators must rec-
ognize the complexity and time con-
straints that accompany the pursuit 
of patent protection and create a cul-
ture in which faculty are supported in 
the process (Bercovitz and Feldmann, 
2006). Clearly some institutions have 
been much more successful at this than 
others, as demonstrated in Table 1.
The technology-transfer office gen-
erally does not wait for the patent to 
be issued to begin marketing an inven-
tion; it can begin almost immediately. 
Universities establish standard poli-
cies and procedures to ensure that key 
aspects of the process move ahead 
correctly (Bercovitz and Feldmann, 
2006). A nonconfidential disclosure of 
the novel technology is put up on the 
university’s website and into reposi-
tories where individuals looking for 
new technologies know they will find 
useful information. One such reposi-
tory is called Ibridge (http://www.
ibridgenetwork.org), for “intellectual 
property bridge,” where universities 
can make their technologies available 
to the public. Marketing inventions is 
now done largely through this method. 
Technology-transfer offices also are 
likely to do some targeted marketing to 
companies that have previously licensed 
university technologies when a similar 
technology arises (Miller et al., 2009).
When a company sees potential 
for a particular technology, it initiates 
communication with the technolo-
gy-transfer office. The dialog begins 
between the university manager for the 
technology and the business develop-
ment manager for the interested com-
pany. The discussion might require a 
confidential disclosure agreement to 
allow confidential information to be 
exchanged. Faculty are often surprised 
by the need for such arrangements, but 
they are in place to secure business 
opportunities for companies and to 
protect intellectual property. Working 
quickly and effectively to secure such 
documentation is important to a com-
pany as it assesses whether it wishes 
to enter into a partnership with an 
inventor at a university. The ease with 
which this process is conducted sets 
the tone of the relationship for many 
companies (Slowinski and Zerby, 
2008; Sampat, 2010). Alternatively, if 
the technology is covered by an issued 
patent, the interested company may 
just look at the patent, satisfy itself 
that the invention will be useful from 
a business standpoint, and contact 
the technology transfer office to begin 
the licensing process. In either situa-
tion, the office will ask the company 
to provide a plan for commercializing 
the technology. The plan must demon-
strate that the company has the nec-
essary business acumen, marketing 
ability, resources, and development 
capability to move the faculty mem-
ber’s invention forward (Bercovitz and 
Feldmann, 2006).
Technology licensing agreements 
with established companies can result 
in significant income to a univer-
sity. Typical components of a license 
agreement are execution royalties, 
minimum annual royalties, earned 
royalties, and milestone payments. 
Milestone payments are often based on 
events such as completion of the first 
prototype, approval by the Food and 
Drug Administration, or first commer-
cial sale. Such payments can add up—
for a recent license at the University of 
Rochester, the first payment was $1.2 
million. Creating these agreements 
and assessing the business plans of 
licensees requires experience and an 
understanding of the marketplace in 
which the invention is to be sold. For 
faculty and the departments in which 
they work, a good technology-transfer 
office eliminates the headache of try-
ing to move an invention through the 
maze of issues involved in patenting 
and marketing while creating revenue 
that is divided among the inventors, 
the department, and the university.
Some inventions are at such an 
early stage in development that they 
may not be of interest to a large, 
table 3. abbreviated set of claims from US Patent 7,888,392
1.  An oleaginous ointment consisting of a compound represented by formula (I, shown in patent 
diagrams) and an oleaginous base, wherein the compound is dispersed but not dissolved in 
a solid or oily state; and wherein the compound is present in 0.000001% to 0.1% by weight; 
wherein the oleaginous base comprises a purified white petrolatum; and wherein the ointment is 
produced by adding a dispersing compound represented by formula (II) in the oleaginous base.
2.  A method for producing an oleaginous ointment as described above comprising: (i) dispersing 
the compound represented by formula (I) in the oleaginous base in a solid or oily state to obtain 
a dispersion; (ii) adding the dispersion to the oleaginous base maintained at a temperature be-
tween 45 and 55 degrees C; and (iii) mixing the dispersion and the oleaginous base with stirring.
3.  The ointment according to claim 1, wherein the oleaginous base is a white petrolatum which 
has been purified by removing impurities that are absorbable to silica gel.
4.  The ointment according to claim 1, wherein the oleaginous base further comprises one or 
more selected from the group consisting of light liquid paraffin, liquid paraffin, paraffin, 
squalane, methylpolysiloxane, and gelated hydrocarbons.
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established company. In such cases, 
the office can work with the inven-
tor and his or her business partners 
to form a start-up company. Again, 
the support of administration for fac-
ulty creating start-up companies is 
an absolute requirement for success 
(Bercovitz and Feldmann, 2006). No 
department will benefit from revenue 
generated by a successful start-up 
without understanding the require-
ments for success in the endeavor 
and providing help to educate fac-
ulty about how to proceed. Start-ups 
are very time consuming and require 
conflict-of-interest discussions and 
disclosures to clarify the delineation 
between company effort and that of 
the faculty member. Transparency is 
the key to long-term success in such 
situations.
Although many faculty believe their 
invention may be appropriate for pat-
ent protection, only a portion of the 
research discoveries brought to the 
technology-transfer office actually 
end up being patented. Depending on 
the mix of patents (pharma cology ver-
sus devices) and the commitment of 
the institution to technology transfer, 
the rate at which a particular univer-
sity licenses its patents varies. Another 
important caveat is that fewer than 
10% of patents issued are ever made 
into products. Given that the research-
to-patent-to-market process is so 
complex and difficult to navigate, and 
is far outside the training and exper-
tise of faculty inventors, it is easy to 
see how so many useful inventions 
end up derailed. Supportive, visionary 
departmental and university leader-
ship is necessary for achieving suc-
cess. A technology-transfer office that 
is knowledgeable and aggressive in 
marketing inventions is also very valu-
able in obtaining returns from faculty 
inventions (Bercovitz and Feldmann, 
2006). Royalty revenue is big busi-
ness for universities, so they have a 
vested interest in ensuring that their 
technology-transfer office is effec-
tive in supporting faculty inventors. 
Departments that recognize talent 
for invention in their faculty, edu-
cate them in appropriate documenta-
tion methodology, and support them 
through the long process to success 
are well positioned to benefit from 
the opportunities that licensing and 
business start-ups present for enrich-
ing the intellectual, research, and 
patient-care environments in their 
departments. Ultimately, patients may 
be the biggest winners when universi-
ties commit the resources necessary to 
translate discovery into practice.
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